Research

Is adiponectin associated with acute myocardial infarction in Iranian non obese patients?

Mohammad Shojaie¹ , Abdoreza Sotoodah² and Ghafar Shafaie³

¹  Cardiology Department, Jahrom Medical University, Jahrom, Iran

²  Immunology Department, Jahrom Medical University, Jahrom, Iran

³  Peymanieh Hospital, Jahrom Medical University, Jahrom, Iran

author email corresponding author email

Lipids in Health and Disease 2009, 8:17doi:10.1186/1476-511X-8-17

Published:	28 May 2009

Abstract

Backgrounds

Adiponectin is an adipose tissue-derived mediator with significant anti-atherogenic properties. A few studies were done in acute phase of myocardial infarction especially in non obese patients. We design a study to investigate the association between adiponectin concentration and acute phase of myocardial infarction in non obese patients.

Methods

This case-control study was done in Paymaneah Hospital (Jahrom, Iran) from Feb 2007 to May 2008. Plasma adiponectin levels were measured in 43 patients with AMI (mean age: 62.7 ± 13.3 years, male: 67.4%) at the first 24 hours of admission and 43 normal controls (mean age: 62.1 ± 12.3 years, male: 55.8%) matched for age, sex and other CAD risk factors.

Results

Adiponectin levels in patients with AMI (3.36 μg/mL) were significantly lower than that of the control group (5.03 μg/mL) (p < 0.0001). Lower adiponectin were independently associated with higher risk of AMI (odds ratio = 8.97; 95% CIs: 2.3–34.5; p = 0.001). Adiponectin levels negatively correlated with triglyceride (r = -0.46, p = 0.002) and total cholesterol (r = -0.32, p = 0.03) in the case group and with body mass index (BMI) in control subjects.

Conclusion

The present study showed that adiponectin was associated with AMI in non obese patients but it is not related to sex, age and other CAD risk factors.